Quantbot Technologies LP Invests $907,000 in Addus HomeCare Corporation $ADUS

Key Points

• Quantbot Technologies LP has acquired 9,167 shares of Addus HomeCare Corporation valued at approximately $907,000 during the first quarter.
• Analysts are generally positive about Addus HomeCare, with several firms raising their price targets and a consensus rating of "Buy".
• Addus HomeCare recently reported a 21.8% increase in revenue year-over-year, with earnings per share beating consensus estimates by $0.04.

Quantbot Technologies LP purchased a new stake in Addus HomeCare Corporation (NASDAQ:ADUS - Free Report) during the first quarter, according to its most recent filing with the SEC. The fund purchased 9,167 shares of the company's stock, valued at approximately $907,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Dimensional Fund Advisors LP increased its holdings in Addus HomeCare by 1.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 692,713 shares of the company's stock valued at $86,833,000 after acquiring an additional 10,434 shares during the last quarter. WCM Investment Management LLC increased its holdings in Addus HomeCare by 4.9% in the 1st quarter. WCM Investment Management LLC now owns 494,791 shares of the company's stock valued at $48,143,000 after acquiring an additional 23,176 shares during the last quarter. Principal Financial Group Inc. increased its holdings in Addus HomeCare by 18.3% in the 1st quarter. Principal Financial Group Inc. now owns 475,818 shares of the company's stock valued at $47,054,000 after acquiring an additional 73,720 shares during the last quarter. Wellington Management Group LLP increased its holdings in Addus HomeCare by 25.8% in the 1st quarter. Wellington Management Group LLP now owns 471,935 shares of the company's stock valued at $46,670,000 after acquiring an additional 96,823 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in Addus HomeCare by 19.8% in the 1st quarter. Invesco Ltd. now owns 414,705 shares of the company's stock valued at $41,010,000 after acquiring an additional 68,585 shares during the last quarter. 95.35% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Addus HomeCare news, EVP Brian Poff sold 7,739 shares of the company's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $116.82, for a total value of $904,069.98. Following the transaction, the executive vice president directly owned 56,980 shares in the company, valued at $6,656,403.60. This represents a 11.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Veronica Hill-Milbourne sold 1,571 shares of the company's stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $114.93, for a total transaction of $180,555.03. Following the completion of the transaction, the director owned 5,067 shares in the company, valued at $582,350.31. This represents a 23.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 34,310 shares of company stock worth $3,958,375 in the last three months. Corporate insiders own 4.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ADUS shares. TD Cowen lifted their price target on shares of Addus HomeCare from $135.00 to $139.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Royal Bank Of Canada boosted their target price on shares of Addus HomeCare from $133.00 to $134.00 and gave the stock an "outperform" rating in a report on Friday, August 22nd. Wall Street Zen upgraded shares of Addus HomeCare from a "hold" rating to a "buy" rating in a report on Sunday, June 29th. Macquarie restated an "outperform" rating and issued a $133.00 target price on shares of Addus HomeCare in a report on Tuesday, June 10th. Finally, JMP Securities restated a "market outperform" rating and issued a $150.00 target price on shares of Addus HomeCare in a report on Wednesday, July 16th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $138.38.

Addus HomeCare Trading Down 0.4%

Shares of ADUS stock traded down $0.40 during trading hours on Friday, reaching $114.92. 21,464 shares of the stock were exchanged, compared to its average volume of 189,092. Addus HomeCare Corporation has a 12-month low of $88.96 and a 12-month high of $136.72. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.17. The company's 50-day moving average price is $112.03 and its 200-day moving average price is $107.00. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of 25.38, a price-to-earnings-growth ratio of 1.76 and a beta of 0.80.

Addus HomeCare (NASDAQ:ADUS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $1.49 EPS for the quarter, topping analysts' consensus estimates of $1.45 by $0.04. Addus HomeCare had a net margin of 6.51% and a return on equity of 9.39%. The firm had revenue of $349.44 million during the quarter, compared to analysts' expectations of $345.71 million. During the same period in the previous year, the company earned $1.35 EPS. The firm's revenue for the quarter was up 21.8% compared to the same quarter last year. As a group, equities analysts anticipate that Addus HomeCare Corporation will post 4.59 earnings per share for the current year.

Addus HomeCare Company Profile

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.